Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia

BACKGROUND: Inhibitors of proprotein convertase subtilisin kexin 9 are indicated in Canada for treatment of patients with familial hypercholesterolemia (FH). Classically, FH is considered to be a monogenic condition caused by rare pathogenic mutations; however, some patients have hypercholesterolemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Timothy, Iacocca, Michael A., Ban, Matthew R., Hegele, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063626/
https://www.ncbi.nlm.nih.gov/pubmed/32159093
http://dx.doi.org/10.1016/j.cjco.2019.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063626/
https://www.ncbi.nlm.nih.gov/pubmed/32159093
http://dx.doi.org/10.1016/j.cjco.2019.02.005

Ejemplares similares